PE20040171A1 - BICYCLE HETEROCYCLES, MEDICINES CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURES FOR THEIR PREPARATION - Google Patents

BICYCLE HETEROCYCLES, MEDICINES CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURES FOR THEIR PREPARATION

Info

Publication number
PE20040171A1
PE20040171A1 PE2003000384A PE2003000384A PE20040171A1 PE 20040171 A1 PE20040171 A1 PE 20040171A1 PE 2003000384 A PE2003000384 A PE 2003000384A PE 2003000384 A PE2003000384 A PE 2003000384A PE 20040171 A1 PE20040171 A1 PE 20040171A1
Authority
PE
Peru
Prior art keywords
amino
bicycle
phenyl
ilo
buten
Prior art date
Application number
PE2003000384A
Other languages
Spanish (es)
Inventor
Frank Himmelsbach
Flavio Solca
Birgit Jung
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20040171A1 publication Critical patent/PE20040171A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A HETEROCICLOS BICICLICOS DE FORMULA I DONDE Ra ES HIDROGENO, ALQUILO C1-C4; Rb ES FENILO, BENCILO O 1-FENILETILO, ENTRE OTROS; Rc ES HIDROGENO, FLUOR, CLORO, BROMO, HIDROXI, ENTRE OTROS; A ES GRUPO IMINO O ALQUIL(C1-C4)-IMINO; B ES CARBONILO O SULFONILO; C ES 1,3-ALENILENO, 1,1-VINILENO, 1,2-VINILENO, ENTRE OTROS; D ES ALQUILENO C1-C4 DE CADENA LINEAL O RAMIFICADO; E ES PIRROLIDIN-1-ILO, PIPERIDIN-1-ILO U HOMOPIPERIDIN -1-ILO, ENTRE OTROS; X ES UN GRUPO METINO SUSTITUIDO CON GRUPO CIANO, NITROGENO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS:4-[(3-CLORO-4-FLUORO-FENIL)AMINO]-6-{[4-((1S,4S)-2-OXA-5-AZA-BICICLO[2.2.1]HEPT-5-IL)-1-OXO-2-BUTEN-1-IL]AMINO}-7-CICLOPROPILMETOXI-QUINAZOLINA,4-[(3-CLORO-4-FLUORO-FENIL)AMINO]-6-{[4-((1S,4S)-2-OXA-5-AZA-BICICLO[2.2.1]HEPT-5-IL)-1-OXO-2-BUTEN-1-IL]AMINO}-7-CICLOPETILOXI-QUINAZOLINA,4-[(3-CLORO-4-FLUORO-FENIL)AMINO]-6-{[4-((1S,4S)-2-OXA-5-AZA-BICICLO[2.2.1]HEPT-5-IL)-1-OXO-2-BUTEN-1-IL]AMINO}-7-[(S)-(TETRAHIDROFURAN-3-IL)OXI]-QUINAZOLINA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS MENCIONADOS TIENEN ACCION INHIBIDORA SOBRE LA TRANSDUCCION DE SENAL MEDIADA POR TIROSINCINASAS Y SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES TUMORALES E HIPERPLASIA PROSTATICA BENIGNA (BHP)REFERS TO BICYCLE HETEROCYCLES OF FORMULA I WHERE Ra IS HYDROGEN, C1-C4 ALKYL; Rb IS PHENYL, BENZYL OR 1-PHENYLETHYL, AMONG OTHERS; Rc IS HYDROGEN, FLUORINE, CHLORINE, BROMINE, HYDROXY, AMONG OTHERS; A ES GROUP IMINO OR ALQUIL (C1-C4) -IMINO; B IS CARBONYL OR SULPHONYL; C IS 1,3-ALENYLENE, 1,1-VINYLENE, 1,2-VINYLENE, AMONG OTHERS; D IS LINEAR OR BRANCHED CHAIN C1-C4 ALKYLENE; E IS PIRROLIDIN-1-ILO, PIPERIDIN-1-ILO OR HOMOPIPERIDIN -1-ILO, AMONG OTHERS; X IS A METINO GROUP SUBSTITUTED BY CIANO GROUP, NITROGENO, AMONG OTHERS. THE PREFERRED COMPOUNDS ARE: 4 - [(3-CHLORO-4-FLUORO-PHENYL) AMINO] -6 - {[4 - ((1S, 4S) -2-OXA-5-AZA-BICICLO [2.2.1] HEPT- 5-IL) -1-OXO-2-BUTEN-1-IL] AMINO} -7-CYCLOPROPYLMETOXY-QUINAZOLINE, 4 - [(3-CHLORO-4-FLUORO-PHENYL) AMINO] -6 - {[4- ( (1S, 4S) -2-OXA-5-AZA-BICYCLE [2.2.1] HEPT-5-IL) -1-OXO-2-BUTEN-1-IL] AMINO} -7-CYCLOPETHYLOXY-QUINAZOLINE, 4- [(3-CHLORO-4-FLUORO-PHENYL) AMINO] -6 - {[4 - ((1S, 4S) -2-OXA-5-AZA-BICYCLE [2.2.1] HEPT-5-IL) -1 -OXO-2-BUTEN-1-IL] AMINO} -7 - [(S) - (TETRAHIDROFURAN-3-IL) OXY] -QUINAZOLINE, AMONG OTHERS. IT ALSO REFERS TO A PROCEDURE FOR PREPARATION. THE MENTIONED COMPOUNDS HAVE INHIBITING ACTION ON SIGNAL TRANSDUCTION MEDIATED BY TIROSINKINASES AND ARE USEFUL FOR THE TREATMENT OF TUMOR DISEASES AND BENIGN PROSTATIC HYPERPLASIA (BHP)

PE2003000384A 2002-04-19 2003-04-15 BICYCLE HETEROCYCLES, MEDICINES CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURES FOR THEIR PREPARATION PE20040171A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10217689A DE10217689A1 (en) 2002-04-19 2002-04-19 Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation

Publications (1)

Publication Number Publication Date
PE20040171A1 true PE20040171A1 (en) 2004-06-02

Family

ID=29224623

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000384A PE20040171A1 (en) 2002-04-19 2003-04-15 BICYCLE HETEROCYCLES, MEDICINES CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURES FOR THEIR PREPARATION

Country Status (10)

Country Link
EP (1) EP1499619A1 (en)
JP (1) JP4527406B2 (en)
AR (1) AR039571A1 (en)
AU (1) AU2003226806A1 (en)
CA (1) CA2484395C (en)
DE (1) DE10217689A1 (en)
PE (1) PE20040171A1 (en)
TW (1) TW200408643A (en)
UY (1) UY27767A1 (en)
WO (1) WO2003089439A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100709909B1 (en) 1999-06-21 2007-04-24 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 Bicyclic heterocycles, medicaments containing these compounds and methods for the production thereof
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
ES2400339T3 (en) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compounds, pharmaceutical compositions thereof and their use in the treatment of cancer
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
JP4638436B2 (en) 2003-09-26 2011-02-23 エグゼリクシス， インコーポレイテッド c-Met modulators and uses thereof
CA2565812C (en) * 2004-05-06 2012-03-13 Warner-Lambert Company Llc 4-phenylamino-quinazolin-6-yl-amides
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc Compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
KR100832594B1 (en) 2005-11-08 2008-05-27 한미약품 주식회사 Quinazoline derivatives as an multiplex inhibitor and method for the preparation thereof
US8404697B2 (en) 2005-11-11 2013-03-26 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
NZ576065A (en) 2006-09-18 2011-12-22 Boehringer Ingelheim Int Method for treating cancer harboring egfr mutations
TWI577664B (en) 2009-01-16 2017-04-11 艾克塞里克斯公司 Malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, pharmaceutical composition comprising the same and use thereof
CN102711472B (en) 2009-07-02 2015-12-02 江苏康缘药业股份有限公司 Phosphorous quinazoline compound and using method thereof
SI2451445T1 (en) 2009-07-06 2019-07-31 Boehringer Ingelheim International Gmbh Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
CN102020639A (en) 2009-09-14 2011-04-20 上海恒瑞医药有限公司 6-amido quinazoline or 3-cyano quinoline derivative, preparation method thereof and application of derivative to medicament
CN103748080B (en) 2011-05-26 2016-09-28 山东轩竹医药科技有限公司 Quinazoline derivative species tyrosine kinase inhibitor and preparation method and application
CN103874696B (en) * 2011-10-12 2015-06-03 苏州韬略生物科技有限公司 Quinazoline derivatives as kinases inhibitors and methods of use thereof
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
WO2020068867A1 (en) 2018-09-25 2020-04-02 Black Diamond Therapeutics, Inc. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0892789T4 (en) * 1996-04-12 2010-04-06 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) * 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
SI2253620T1 (en) * 1998-09-29 2014-06-30 Wyeth Holdings Llc Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
JP3751201B2 (en) * 1999-02-27 2006-03-01 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 4-Amino-quinazoline derivatives and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
DE19908567A1 (en) * 1999-02-27 2000-08-31 Boehringer Ingelheim Pharma New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases
KR100709909B1 (en) * 1999-06-21 2007-04-24 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 Bicyclic heterocycles, medicaments containing these compounds and methods for the production thereof
ATE350378T1 (en) * 2000-04-08 2007-01-15 Boehringer Ingelheim Pharma BICYCLIC HETEROCYCLES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS, THEIR USE AND METHOD FOR THEIR PRODUCTION
DE10017539A1 (en) * 2000-04-08 2001-10-11 Boehringer Ingelheim Pharma New 6-acylamino-4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors or respiratory or gastrointestinal diseases
DE10042061A1 (en) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10042062A1 (en) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and methods of preparation

Also Published As

Publication number Publication date
AU2003226806A1 (en) 2003-11-03
CA2484395C (en) 2011-11-22
WO2003089439A1 (en) 2003-10-30
JP2005526837A (en) 2005-09-08
EP1499619A1 (en) 2005-01-26
DE10217689A1 (en) 2003-11-13
JP4527406B2 (en) 2010-08-18
UY27767A1 (en) 2003-11-28
TW200408643A (en) 2004-06-01
AR039571A1 (en) 2005-02-23
CA2484395A1 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
PE20040171A1 (en) BICYCLE HETEROCYCLES, MEDICINES CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURES FOR THEIR PREPARATION
MA26994A1 (en) QUINAZOLINES AS INHIBITORS OF MMP-13
LV12639B (en) Biphenylsulfonamide is a dual angiotensin and endothelin receptor antagonist
CO5021213A1 (en) NF-k8 TRANSCRIPTION FACTOR INHIBITORS
PE20040169A1 (en) QUINAZOLIN-4-AMINE DERIVATIVES AS INHIBITORS OF SIGNAL TRANSDUCTION INDUCED BY TYROSINQUINASES
NO20011338L (en) Contrast agent that fluoresces in an area near the infrared area and fluorescence imaging
BR9804504A (en) Isoquinoline-3-carboxamides substituted, their preparation and use as pharmaceutical substances
EA200400054A1 (en) SUBSTITUTED NAFTILINDOL DERIVATIVES AS AN INHIBITORS INHIBITOR INHIBITOR PLASMINOGEN TYPE 1 (PAI-1) INHIBITOR
CY1108714T1 (en) CGRP RACE COMPETITORS
PE20050073A1 (en) NEW SPIROCONDENSED QUINAZOLINONES INHIBITING PHOSPHODIESTERASE
UY25131A1 (en) DERIVATIVES OF ARILOXIARILSULFONILAMINO HIDROXAMICOS ACIDS
CO5540344A2 (en) MEDICINES
ES2266459T3 (en) USE OF SUBSTITUTED AZETIDINONE COMPOUNDS FOR THE TREATMENT OF SITOSTEROLEMIA.
TNSN02012A1 (en) NOVEL PYRIMIDINE DERIVATIVES OF MMP INHIBITORS, AND COMPOSITIONS CONTAINING THEM
GT200300059A (en) USEFUL COMPOUNDS IN THERAPY
SV2002000047A (en) PROCEDURES AND INTERMEDIATES TO PREPARE ANTI-TARGET COMPOUNDS REF.PC10188 ABCZ
PE20060381A1 (en) HEPATITIS C INHIBITOR DIPEPTIDE ANALOGS
EA200400023A1 (en) HIV PROTEASE INHIBITORS, CONTAINING THEIR COMPOSITIONS, THEIR PHARMACEUTICAL USE AND MATERIALS FOR THEIR SYNTHESIS
TR199901191T2 (en) Use of benzamidoaldehydes as cysteine protease inhibitors.
TNSN02008A1 (en) NEW MMP INHIBITOR ISOPHTHALIC ACID DERIVATIVES AND COMPOSITIONS CONTAINING THEM
DK1583541T3 (en) Compounds and Methods to Increase Neurogenesis
CO5011115A1 (en) CHEMIOQUINE COMPOUNDS AND METHODS
PE107999A1 (en) 3-AMIDINOANILINE DERIVATIVES, ACTIVATED BLOOD COAGULATION FACTOR X INHIBITORS AND INTERMEDIARIES THEREOF
DE69735442D1 (en) ANTIDIABETIC AGENTS
SV2003000633A (en) NEW TIADIAZOLS AND OXADIAZOLS AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASA-7

Legal Events

Date Code Title Description
FD Application declared void or lapsed